Company Overview
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -19.87% |
| 6 Months: | -61.18% |
| 3 Months: | -22.84% |
| 1 Month: | -23.31% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)33.67 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 65.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NMRA Neumora Therapeutics, Inc. PHARMA | 1.25 | -1.02 | $234.87M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 70.94M | 54.04M | 57.70M | 58.48M | 52.86M |
| Operating Income | - | - | -30.60M | -39.17M | -42.06M | -56.86M | -60.07M | -63.82M | -76.65M | -70.94M | -54.04M | -57.70M | -58.48M | -52.86M |
| EBITDA | - | - | - | - | - | - | - | - | - | -67.73M | -54.02M | -55.98M | -57.41M | -51.57M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 0 | - | 747.00K | 2.04M | 1.85M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -67.89M | -52.71M | -56.76M | -59.45M | -53.43M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 105.00K | 25.00K | 0 | 0 | 30.00K |
| Net Income | -43.04M | -30.37M | -29.34M | -35.62M | -38.54M | -53.03M | -53.72M | -58.70M | -72.55M | -67.99M | -52.73M | -56.76M | -59.45M | -53.46M |
| Diluted EPS | - | - | -1.06 | -1.22 | -1.28 | -1.14 | -0.34 | -0.37 | -0.45 | -0.42 | -0.33 | -0.35 | -0.35 | -0.30 |
| R&D Expense | - | - | 22.55M | 29.48M | 32.77M | 41.60M | 45.76M | 48.63M | 60.63M | 52.15M | 38.72M | 40.52M | - | 38.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 135.87M | 252.10M | 263.46M | 241.16M |
| Operating Income | -135.87M | -252.10M | -263.46M | -241.16M |
| EBITDA | -135.28M | -251.43M | -262.83M | -233.37M |
| Interest Expense | - | - | - | 3.22M |
| Pretax Income | -130.90M | -235.66M | -243.61M | -236.80M |
| Tax Provision | 0 | 268.00K | 178.00K | 130.00K |
| Net Income | -130.90M | -235.93M | -243.79M | -236.93M |
| Diluted EPS | -0.86 | -3.63 | -1.53 | -1.45 |
| R&D Expense | 91.75M | 142.72M | 200.93M | 176.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 426.23M | 496.19M | 316.97M | 191.05M |
| Current Assets | - | 387.95M | 478.28M | 314.06M | 190.54M |
| Cash & Equivalents | - | 240.94M | 374.04M | 142.15M | 182.53M |
| Inventory | - | - | - | - | - |
| Receivables | 200.00K | 919.00K | 939.00K | - | - |
| Total Liabilities | - | 873.08M | 27.12M | 29.91M | 87.18M |
| Current Liabilities | - | 23.70M | 25.11M | 29.89M | 32.45M |
| Long Term Debt | - | - | - | - | 54.53M |
| Total Debt | - | 8.44M | 5.23M | 1.85M | 55.01M |
| Total Equity | - | -446.85M | 469.08M | 287.06M | 103.87M |
| Shares Outstanding | - | 151.95M | 158.83M | 161.71M | 174.26M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -114.90M | -163.28M | -182.94M | -206.44M |
| Investing Cash Flow | - | -168.01M | 64.39M | -70.56M | 168.52M |
| Financing Cash Flow | - | 115.74M | 231.94M | 21.60M | 77.09M |
| Capital Expenditure | -817.00K | -511.00K | -117.00K | - | - |
| Free Cash Flow | - | -115.41M | -163.40M | -182.94M | -206.44M |
| Net Change in Cash | - | -167.17M | 133.04M | -231.89M | 39.17M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 29.3% | -50.3% | -84.9% | -228.1% |
| ROCE % | -33.8% | -53.5% | -91.8% | -152.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Siren, L.L.C. | 4.52% | 8.50M | $6.20M |
| 2 | Blackrock Inc. | 4.15% | 7.79M | $5.69M |
| 3 | Softbank Group Corporation | 3.24% | 6.09M | $4.45M |
| 4 | Vanguard Capital Management LLC | 2.49% | 4.67M | $3.41M |
| 5 | MIC Capital Management UK LLP | 2.37% | 4.46M | $3.26M |
| 6 | FMR, LLC | 1.86% | 3.50M | $2.55M |
| 7 | Wellcome Trust Ltd (the) As Trustee Of The Wellcome Trust | 1.76% | 3.31M | $2.42M |
| 8 | Geode Capital Management, LLC | 1.39% | 2.61M | $1.90M |
| 9 | ICONIQ Capital, LLC | 1.36% | 2.56M | $1.87M |
| 10 | Two Sigma Investments, LP | 1.19% | 2.24M | $1.64M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NMRA
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026 Progressing NMRA-511 in Alzheimer’s disease (AD) agitation and NMRA-898 in schizophrenia with clin…
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical co…
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation
Neumora Therapeutics is back in focus after analysts cut their fair value estimate from US$8.91 to US$6.53 per share, a reduction of about 27% that resets expectations around the stock. Much of this shift tracks recent commentary on the dec…
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is among the best get rich quick stocks to buy right now. On June 18, Mizuho lowered the price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $4, down from $6. This came after the company’s ne…
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the small-cap stocks with potential to rise 1000 percent. The company’s main near-term catalyst is navacaprant, an experimental depression treatment being tested in patients with major depr…
Three pivotal MDD trial failures for Neumora lead to staffing cuts
The KOASTAL 2 and KOASTAL 3 trials also failed to meet their endpoints, with Neumora now culling development of the MDD candidate
NMRA — Frequently Asked Questions
What is the current share price of Neumora Therapeutics, Inc. (NMRA)?
As of 2026-09-19 21:16 PDT, Neumora Therapeutics, Inc. (NMRA) trades at $1.25 on NasdaqGS. Its 52-week range is $0.92 to $3.59.
What is the market capitalisation of NMRA?
Neumora Therapeutics, Inc. (NMRA) has a market capitalisation of $234.87M on NasdaqGS.
What is the P/E ratio of NMRA?
NMRA trades at a trailing price-to-earnings (P/E) ratio of -1.02. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.07.
Is NMRA a good stock to buy?
This page provides a data-driven analysis of Neumora Therapeutics, Inc. (NMRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.